Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

April 13, 2021

7 Steps to an Evidence Dossier for Wearables

There has been an increasing use of digital measures in drug development recently. New wearables technologies can help...

Read article

March 31, 2021

Wearables and Decentralization

As decentralized clinical trials become more attractive in an era of COVID-19, the role of wearables in clinical...

Read article

March 19, 2021

5 Steps to Regulatory Success with Wearables Designs

The use of wearable and digital technology requires considerations for both drugs and devices regulations, and...

Read article

March 12, 2021

Wearables: Translating raw data to actionable information

With wearables likely to become a regular part of clinical trial design, statisticians could benefit by familiarizing...

Read article

February 25, 2021

Use of Wearables in Confirmatory Clinical Trials

The convergence of several distinct trends has made wearables an increasingly attractive option for use in confirmatory...

Read article

February 11, 2021

The biostats and clinical overview of a growing clinical strategy

The past two years have witnessed a heightened interest in the use of wearables in clinical development. The unexpected...

Read article